# Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

> **NCT06410651** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 53 (estimated)

## Conditions studied

- Esophageal Cancer
- Nimotuzumab
- Chemoradiotherapy
- Chemotherapy
- Immunotherapy

## Interventions

- **COMBINATION_PRODUCT:** Nimotuzumab with chemoradiotherapy

## Key facts

- **NCT ID:** NCT06410651
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06410651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06410651, "Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06410651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*